The Trend of CEACAM3 Blood Expression as Number Index of the CTCs in the Colorectal Cancer Perioperative Course

Table 1

Clinical/pathological characteristics of patients and associated CEACAM3 levels.

	Time (days)	CEACAM3 levels				CEA values (Mean ± SD)
		Mean ± SD	Mean; 95% CI	Median	Range
All cases ()	0	4.01 ± 2.42	3.21 to 4.81	3.54	−2.81 to 8.36	4.95 ± 2.12
	1	3.43 ± 2.69	2.54 to 4.31	3.02	−5.77 to 7.45	3.93 ± 2.63
	5	3.46 ± 2.21	2.73 to 4.18	3.26	−0.95 to 7.39	4.20 ± 1.84
	180	1.22 ± 1.62	0.69 to 1.76	1.19	−3.38 to 4.36	3.80 ± 2.32
Sex
Female ()	0	4.39 ± 2.34	3.14 to 5.64	4.21	1.53 to 8.36	4.98 ± 1.48
	1	3.69 ± 2.54	2.33 to 5.04	3.42	0.03 to 7.21	3.69 ± 1.82
	5	3.65 ± 2.37	2.39 to 4.91	2.56	0.89 to 7.14	3.65 ± 2.12
	180	0.97 ± 1.87	−0.03 to 1.96	0.90	−3.38 to 4.36	3.50 ± 1.65
Male ()	0	3.74 ± 2.50	2.63 to 4.84	3.29	−2.81 to 8.03	4.28 ± 1.89
	1	3.24 ± 2.84	1.98 to 4.50	3.02	−5.77 to 7.45	4.30 ± 2.74
	5	3.31 ± 2.13	2.37 to 4.26	3.48	−0.95 to 7.39	3.90 ± 1.65
	180	1.41 ± 1.43	0.77 to 2.04	1.25	−1.96 to 4.21	2.50 ± 1.43
Site
Caecum/ascending ()	0	3.13 ± 3.17	0.86 to 5.39	2.77	−2.81 to 8.03	4.37 ± 2.35
	1	3.50 ± 2.73	1.54 to 5.45	3.16	−0.33 to 7.45	4.25 ± 1.89
	5	2.94 ± 2.72	0.99 to 4.88	2.14	−0.95 to 7.39	4.50 ± 2.38
	180	1.11 ± 1.35	0.15 to 2.08	0.83	−1.24 to 3.14	3.50 ± 2.62
Descending/sigmoid colon ()	0	5.06 ± 1.76	4.00 to 6.13	5.19	1.87 to 7.73	4.36 ± 1.72
	1	3.78 ± 2.39	2.34 to 5.22	4.22	0.03 to 6.74	4.20 ± 1.69
	5	4.01 ± 2.06	2.76 to 5.26	4.01	1.58 to 7.14	3.90 ± 2.15
	180	1.16 ± 2.09	−0.10 to 2.42	1.20	−3.38 to 4.36	2.50 ± 1.62
Rectum ()	0	3.69 ± 2.17	2.49 to 4.89	2.59	1.24 to 8.36	5.09 ± 2.33
	1	3.08 ± 3.03	1.40 to 4.76	2.89	−5.77 to 7.21	4.90 ± 2.63
	5	3.32 ± 2.00	2.21 to 4.43	3.39	1.02 to 6.51	4.90 ± 1.56
	180	1.35 ± 1.42	0.56 to 2.13	1.25	−1.96 to 4.21	3.50 ± 1.68
Stage pT
pT1-pT2 ()	0	3.37 ± 1.99	2.21 to 4.52	2.59	1.12 to 8.03	5.06 ± 2.78
	1	2.36 ± 3.07	0.59 to 4.13	2.44	−5.77 to 7.45	4.96 ± 1.63
	5	2.32 ± 1.86	1.24 to 3.39	1.64	0.89 to 7.39	4.70 ± 2.58
	180	0.91 ± 1.45	0.07 to 1.75	1.01	−3.38 to 2.99	2.78 ± 1.13
pT3-pT4 ()	0	4.39 ± 2.61	3.29 to 5.49	4.88	−2.81 to 8.36	4.47 ± 2.27
	1	4.05 ± 2.28	3.09 to 5.02	4.23	−0.33 to 7.21	4.25 ± 1.36
	5	4.12 ± 2.16	3.21 to 5.03	4.11	−0.95 to 7.14	4.20 ± 2.62
	180	1.40 ± 1.72	0.68 to 2.13	1.23	−1.96 to 4.36	3.98 ± 2.54
Pathological stage
I ()	0	3.51 ± 2.00	2.30 to 4.72	2.59	1.12 to 8.03	5.06 ± 3.03
	1	2.48 ± 3.16	0.57 to 4.39	2.47	−5.77 to 7.45	4.70 ± 2.65
	5	2.43 ± 1.89	1.28 to 3.57	1.69	1.02 to 7.39	4.67 ± 2.35
	180	0.93 ± 1.51	0.02 to 1.84	1.01	−3.38 to 2.99	4.23 ± 1.89
II ()	0	5.34 ± 2.01	4.06 to 6.62	5.32	2.31 to 8.36	4.58 ± 1.98
	1	4.91 ± 1.94	3.68 to 6.15	5.17	0.58 to 7.21	4.90 ± 1.85
	5	4.64 ± 1.72	3.54 to 5.73	4.90	1.84 to 6.51	4.62 ± 1.98
	180	1.36 ± 1.45	0.44 to 2.28	1.29	−1.96 to 3.60	4.36 ± 2.62
III ()	0	3.29 ± 2.79	1.60 to 4.97	2.99	−2.81 to 7.73	2.66 ± 2.72
	1	3.01 ± 2.35	1.59 to 4.42	2.94	−0.33 to 6.74	2.98 ± 2.65
	5	3.40 ± 2.50	1.89 to 4.91	3.56	−0.95 to 7.14	2.48 ± 1.13
	180	1.39 ± 1.95	0.21 to 2.56	0.89	−1.78 to 4.36	2.60 ± 1.64